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Corticotropin-Releasing Hormone Stimulates the
In Situ Generation of Mast Cells from Precursors in
the Human Hair Follicle Mesenchyme
Natsuho Ito1, Koji Sugawara2,3, Enik +o Bodo´4, Masahiro Takigawa1, Nina van Beek2, Taisuke Ito1 and
Ralf Paus2,5
Hair follicles (HFs) maintain a peripheral, functional equivalent of the hypothalamic–pituitary–adrenal (HPA)
axis, whose most proximal element is corticotropin-releasing hormone (CRH). The mast cell (MC)-rich
connective-tissue sheath (CTS) of mouse vibrissa HFs harbors MC precursors. Differentiation of these MC
precursors into mature MCs can be induced by stem cell factor (SCF). We have investigated whether the MC
progenitors of normal human scalp HF CTS respond to stimulation with CRH. Microdissected anagen HFs and
full-thickness scalp skin were treated with CRH (107 M). CRH treatment induced the degranulation of CTS MCs,
in addition to increasing the number of CTS MCs in full-thickness skin and HF organ cultures in situ. In the
latter, cells with characteristic MC features emigrated from the CTS. CRH-receptor protein expression in the CTS
was colocalized with Kit expression on some CTS MCs in situ. CRH treatment upregulated SCF mRNA and
protein expression within the HF epithelium. In skin organ culture, CRH-induced degranulation of CTS MCs
was abolished by anti-SCF antibody. We demonstrate that human skin is an extramedullary reservoir for MC
precursors, and we have identified a regulatory loop between CRH and SCF signaling. This highlights a
previously unpublished finding about neuroendocrine control of human MC biology.
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INTRODUCTION
Mast cells (MCs) are now well recognized to have multiple
biological effects, well beyond their role as a key protagonist
in allergic responses. Indeed, it is now documented that MCs
are important in both innate immunity and acquired
immunity, inflammation, angiogenesis, wound healing, and
the control of tumor growth, under physiological and
pathological conditions (Maurer et al., 1998; Weber et al.,
2003; Theoharides and Cochrane, 2004; Theoharides et al.,
2004; Maurer and Metz, 2005; Schro¨der et al., 2006; Weller
et al., 2006; Metz and Maurer, 2007; Metz et al., 2008). MCs,
which are derived from bone marrow stem cells, undergo
maturation in peripheral tissues under the control of the Kit
ligand stem cell factor (SCF) (Maurer et al., 1998; Wedemeyer
et al., 2000; Maurer and Metz, 2005), depending on local
microenvironmental cues (Wedemeyer et al., 2000; Paus
et al., 2006). SCF also induces MC proliferation, prevents MC
apoptosis, and enhances mediator and cytokine release by
MCs (Maurer et al., 1998, 2003).
In mammalian skin, MCs preferentially localize to blood
vessels, nerve fibers, and hair follicles (HFs) (Botchkarev
et al., 1997; Maurer et al., 2003). SCF can trigger
MC migration into and/or proliferation within the skin
(Theoharides et al., 2004). Interestingly, SCF-Kit regulatory
networks have been reported in murine contact dermatitis,
where SCF-transgenic mice exhibited a significantly
increased ear-swelling response to allergen and to a contact
irritant. This suggests that the release of soluble SCF from
epidermal keratinocytes can result in a positive feedback
loop that induces increased MC degranulation (Carter et al.,
2008). Intracutaneous MCs operate as ‘‘switchboards,’’
governing neurogenic inflammation and tissue remodeling
(Maurer et al., 1995, 2003; Maurer and Metz, 2005; Paus
et al., 2006; Metz et al., 2008). In addition, there is increasing
awareness that MCs participate in neuroendocrine signaling
loops, e.g., by the production and secretion of proopiome-
lanocortins to which MCs then show a receptor-dependent
secretory response (Henz, 2008) and by responding to
stimulation by corticotropin-releasing hormone (CRH), a
key neuroendocrine mediator of systemic stress responses
(Theoharides et al., 2004; Paus et al., 2006).
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These functions appear to be particularly important for HF-
associated MCs, which are found in relatively high density
within the specialized connective-tissue sheath (CTS) of the
HF (Botchkarev et al., 1995, 1997; Maurer et al., 1995; Peters
et al., 2007). Here, they may be actively involved in the
control of hair growth (Paus et al., 1994; Maurer et al., 1995;
Botchkarev et al., 1997; Ito et al., 2004a). Even in long-term
human skin organ culture, perifollicular MCs survive and
remain active (Lu et al., 2007). Interestingly, it has been
reported that MCs can be generated de novo in mice from the
CTS of murine vibrissa HFs in vitro by stimulation with SCF
(Kumamoto et al., 2003). This raised the intriguing possibility
that murine skin MCs can be generated, in the absence of
hematopoietic stem cell sources, from resident intracuta-
neous progenitor cells associated with the HF mesenchyme.
However, this intriguing and important observation
remains to be systematically followed up, namely, in the
human system.
In the context of our ongoing exploration of HF
neuroendocrinology in general, and our continued interest
in the role of MCs in hair biology in particular (Paus et al.,
1994, 1998; Botchkarev et al., 1995, 1997), we have now
investigated the hypothesis that the mesenchyme of human
HFs harbors resident MC precursors and that this may be
influenced by CRH. This was prompted by the recent
discovery that human HFs show a fully functional peripheral
equivalent of the hypothalamic–pituitary–adrenal stress
response system, the hypothalamic–pituitary–adrenal (HPA)
axis, including expression of its proximal chief regulatory
element, CRH, on both the gene and the protein levels
(Slominski et al., 2004; Ito et al., 2004a, 2005a). Also, it had
been shown that organ culturing of human scalp HFs in the
presence of CRH is associated with substantial degranulation
of CTS MCs (Singh et al., 1999a; Ito et al., 2005a). Therefore,
we investigated whether CRH promotes the generation of
mature MCs from resident precursor cells in the human CTS,
similar to the effect reported for SCF in mouse vibrissa HFs
(Singh et al., 1999b).
Evidence continues to accumulate that CRH has multiple
biological functions in addition to its classical role as a
potent, central stress mediator. For example, CRH is involved
in chronic, stress-associated inflammatory immune responses
(Jessop et al., 2001) that can activate MCs in the context of
stress-induced neurogenic inflammation (Singh et al., 1999b;
Theoharides et al., 2004). Human MCs, which express CRH
receptors (CRH-Rs), have been reported to synthesize and
secrete CRH and respond to CRH-R stimulation by releasing
cytokines and other proinflammatory mediators (Theoharides
et al., 1998; Singh et al., 1999a). Furthermore, acute restraint
stress induced rat intracranial MC activation in a CRH-
dependent manner (Theoharides et al., 1995) and CRH can
trigger rat skin MC degranulation, leading to increased
vascular permeability (Theoharides et al., 1998). CRH also
causes vasodilation in human skin via MC-dependent
pathways (Cromptom et al., 2003). Given that skin MCs
and CRH are central players in the peripheral tissue response
to perceived stress, and that MCs exert their effects as
major stress-receptive sentinels within the cutaneous
neuroimmunoendocrine environment (Theoharides et al.,
2004; Arck et al., 2005; Maurer and Metz, 2005; Paus
et al., 2006; Metz et al., 2008), we investigated the effects of
CRH on human CTS MCs.
Using microdissected, organ-cultured human scalp HFs
(Philpott et al., 1994) as a particularly instructive human
model system for studying the impact of major stress
mediators on peripheral tissue functions (Ito et al., 2005a,
b; Peters et al., 2007), we have specifically explored whether
the CTS of normal human scalp HFs serves as an extra-
medullary cell reservoir for the de novo generation of
functional skin MCs and whether CRH has any role in this.
Because we were exclusively interested in the CRH response
of normal, unmanipulated human skin MCs that grow within
their natural connective-tissue environment, we purposely
abstained from using human MC (leukemia) lines.
RESULTS
CRH promotes human skin MC degranulation in situ
First, we investigated whether CTS and interfollicular MCs are
functional CRH targets in normal human scalp skin.
Untreated human scalp skin contained numerous degranu-
lated and nondegranulated, toluidine blue/Leder-esterase-
positive MCs, which were particularly prominent in the
perifollicular dermis HFs (Figure 1a) and in the CTS of organ-
cultured human scalp HF (Figure 1b). When organ-cultured
human HFs were treated with 107 M CRH for 6 days, the
number of degranulated CTS MCs increased significantly,
compared with vehicle-treated controls (Figure 1b and c).
This MC secretagogue effect of CRH was even more
pronounced in full-thickness human scalp skin organ culture
(Lu et al., 2007). Here, 107 M CRH significantly increased
the number of MCs that were histochemically identifiable as
strongly degranulated, in both the HF CTS (Figure 1d, f, and g)
and the interfollicular dermis (Figure 1e).
CRH increases the number of CTS MCs in cultured human HFs
in vitro
The total number of histochemically detectable, toluidine-
blue- or Giemsa-positive CTS MCs was also significantly
increased after 6 days of CRH treatment (Figure 2a). To
identify more immature, histochemically undetectable or
easily missed MCs, we used the highly sensitive tyramide
signal amplification (TSA) immunofluorescence method for
the immunodetection of Kitþ cells, and the obtained results
were compared with the MC histochemistry findings
(Figure 2b). As expected, Kit TSA immunofluoresence was
the most sensitive method for the detection of CTS MCs
(Figure 2b), as it reliably demarcated MCs that were toluidine
blue or Leder esterase negative. In fact, three to four times
more cells with the typical morphology of MCs could be
detected using the Kit TSA method compared with classical
MC histochemistry (Figure 2b). Because MC histochemistry
predominantly visualizes fully mature, differentiated MCs,
this suggests the presence of numerous, relatively immature
MCs in the human CTS, which, also Kitþ , escape detection
by standard histochemistry. Interestingly, CRH treatment
further upregulated the number of Kitþ cells significantly
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(Po0.05; Figure 2c, d). To specifically investigate the effect
of CRH on MC maturation, we investigated tryptase
immunoreactivity (IR) as an optimal MC maturation marker
(TSA immunofluorescence). Indeed, CRH treatment also
significantly increased the number of tryptaseþ cells in the
CTS of organ-cultured human HFs (Figure 2e).
Next, we explored the possibility that MCs in the CTS of
isolated human HFs progressively die with advancing
duration of organ culture and that CRH only retards this
process. However, as shown in Figure 2f and g, the number of
histochemically (Figure 2f) and immunohistologically (Figure
2g) detectable CTS MCs did not decline significantly over
6 days of human HF organ culture (although the absolute
number of detectable CTS MCs was very slightly reduced).
This is perfectly in line with our previous finding that
perifollicular MCs survive and remain active even in long-
term, serum organ culture of full-thickness human scalp skin
after 13 days in vitro (Lu et al., 2007). Importantly, the
number of Kitþ CTS cells in situ even increased significantly
in unstimulated human HFs over 6 days of organ culture
(Figure 2h, i). This makes substantial CTS MC death with
increasing culture duration highly unlikely. Moreover, these
data also suggest that MC growth factors that promote CTS
MC survival, local proliferation, and/or differentiation of
immature MC progenitors constitutively emanate from the
HF epithelium and/or are generated within the CTS—even
under the harsh conditions of long-term, serum-free HF
organ culture.
MCs can arise intracutaneously from resident precursors in the
CTS of human scalp HFs
During these assays, we noted that the total number of MCs
found in the CTS of cultured human HFs was much lower
than that seen in intact human skin in situ. This suggested that
MCs might have emigrated from the CTS, similar to what had
been described for murine vibrissa HFs (Kumamoto et al.,
2003). To test this hypothesis, we cultured human anagen
scalp HFs in RPMI 1640 medium (instead of the regular
Williams’s E medium used for HF organ culture), with the HF
‘‘sandwiched’’ under a cover glass. Within 10 days of culture,
round cells began to emerge from human HF CTS in vitro. In
agreement with the results reported in mice, the number of
these cells, which remained attached to the culture plate,
gradually increased (Figure 3a). Because most of these cells
showed metachromatic granules by toluidine blue histo-
chemistry (Figure 3b) and were tryptaseþ (Figure 3b) and/or
Kitþ (Figure 3b), the majority of the emigrating cells are
probably MCs. Thus, mature MCs can arise from resident
precursors in the CTS of human scalp HFs, independent of
continued access to hematopoietic precursor cells from
bone marrow.
CRH stimulates the emigration of Kitþ cells from the CTS
Because CRH treatment appeared to stimulate this emigration
process (Figure 3a), we next treated human HFs with vehicle
or 107 M CRH for 4 weeks, assessed both tryptase and Kit
immunoreactivity, and counted all round, tryptaseþ or Kitþ
cells. This revealed that CRH significantly increased the
number of the tryptaseþ or Kitþ cells, compared with
controls (Figure 3c, d). Indeed, after 4 weeks, the baseline
number of Kitþ cells in the vehicle control group was
substantially higher (Figure 3d) than that which had been
observed in CTS sections after 6 days of HF organ culture
(Figure 2b). This further suggests substantial expansion and/or
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Figure 1. CRH promotes degranulation of CTS MCs. (a) Toluidine blue
staining. Human skin contains many MCs, especially around the HFs in situ.
(b) Giemsa staining. Microdissected organ-cultured HFs also contain Giemsa-
positive MCs in CTS. Upper picture shows nondegranulated MCs on vehicle-
treated HF. Lower picture shows degranulated MC on CRH-treated HF.
(c) After 6 days of CRH treatment, the number of degranulated CTS MCs
was significantly increased (n¼ 43–64 HFs, Student’s t-test; asterisks indicate
significant differences compared to the vehicle control, *Po0.05). 4-mm Full-
thickness skin biopsies (three or four pieces per group) were organ cultured
(Lu et al., 2007) and treated for 48 hours with vehicle (Williams’s E medium),
107 M CRH, 107 M CRH, and 5 mgml1 anti-SCF antibody. Based on the
number of extracellular granules, three categories of MCs were defined:
0, o5, and 45 extracellular granules. Representative images show a
nondegranulated (o5 granules) and a degranulated (45 granules) MC (f and
g). (d) After 48 hours of CRH treatment, the number of nondegranulated CTS
MCs was significantly decreased, whereas we observed an increase in the
number of degranulated cells. This effect could be abolished by a cotreatment
with anti-SCF. (e) CRH significantly increased the number of degranulated
intrafollicular MCs (n¼ 3–4 biopsies, Mann–Whitney U-test; asterisks indicate
significant differences compared to the vehicle control or as indicated,
*Po0.05). Bars: (a) 100 mm; (b, f, g) 20 mm. CRH, corticotropin-releasing
hormone; CTS, connective-tissue sheath; HF, hair follicle; MC, mast cell;
ORS, outer root sheath; SCF, stem cell factor.
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differentiation of a resident MC precursor pool in the
human CTS.
Next, we examined mRNA levels of c-Kit in the proximal
HF by reverse transcription–PCR. Although Kit IR significantly
increased after CRH treatment (Figure 2c), the steady-state
level of c-Kit transcripts in mRNA, extracted from micro-
dissected human anagen hair bulbs and their CTS, was
not significantly modulated by CRH (data not shown).
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Figure 2. CRH increases the number of tryptase and Kitþ CTS cells. (a) Total number of MCs from each of 10 HFs was counted. After 6 days of CRH treatment,
the total number of CTS MCs was significantly increased (n¼ 28–42 HFs, Student’s t-test; asterisks indicate significant differences compared to the vehicle
control, *Po0.05). (b) Total numbers of CTS MCs detected with toluidine blue, Leder esterase, and Kit staining were compared. (c) Kit was immunostained by
TSA on cultured HFs. Kitþ cells (FITC) were densely distributed in CTS on cultured HFs. (d) After 6 days CRH treatment, the number of Kitþ cells was
significantly increased (n¼ 6 HFs, Student’s t-test; asterisks indicate significant differences compared to the vehicle control, *Po0.05). (e) The number of
tryptaseþ cells was also significantly increased in the CTS of 6 days cultured human HFs with CRH (n¼ 12 HFs, Student’s t-test; asterisks indicate significant
differences compared to the vehicle control, *Po0.05). (f) Total number of CTS MCs detected with Leder esterase histochemistry was compared between freshly
isolated anagen VI HFs and anagen VI HFs cultured for 6 days (n¼ 12 HFs, Student’s t-test). (g) The total number of CTS MCs detected with tryptase
immunohistology was compared between freshly isolated anagen VI HFs and anagen VI HFs cultured for 6 days (n¼ 12 HFs, Student’s t-test). (h) Representative
images of CTS MCs detected with Kit immunohistology. CTS MCs in freshly isolated human HFs (left), CTS MCs in the HFs cultured for 6 days (right). (i) The
number of Kitþ cells was significantly increased in the CTS of human anagen VI HFs cultured for 6 days (n¼ 12 HFs, Student’s t-test; asterisks indicate
significant differences compared to the vehicle control, *Po0.05). Bars: (c, h) 20mm. CRH, corticotropin-releasing hormone; CTS, connective-tissue sheath; HF,
hair follicle; MC, mast cell; NS, not significant; ORS, outer root sheath; SCF, stem cell factor; TSA, tyramide signal amplification.
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In addition, we investigated, by double-immunofluorescence,
Ki-67 expression on Kitþ cells. Double-positive cells were
absent in the human CTS after CRH stimulation (data not
shown). This suggests that the CRH-induced increase in
histochemically or immunohistologically detectable MC
numbers primarily reflects the induction of maturation events
in preexistent, resident, immature MC precursor cells, rather
than local proliferation of mature CTS MCs.
Effects of CHR on CTS MCs involve an indirect mechanism of
action by stimulation of SCF
We then investigated whether CRH affects Kitþ cells directly
or indirectly. We had previously shown that both CRH-Rs
and CRH are abundantly expressed in human HF epithelium
(Ito et al., 2004a, b; Ito et al., 2005a). We now show that
some Kitþ CTS cells are double positive for CRH-R1/2 IR
(Figure 3e), suggesting that at least a subpopulation of human
CTS MCs expresses cognate receptors for CRH. This implies
that, in principle, CRH may directly stimulate at least a
subpopulation of CRH-R1/2þ human CTS MCs.
Given the well-recognized key role of SCF in MC
development, maturation, and function (Maurer et al.,
1998; Wedemeyer et al., 2000; Maurer and Metz, 2005)
and its stimulatory effect on murine CTS MC progenitors
(Kumamoto et al., 2003), we then investigated whether SCF
affects human CTS MCs in situ. Organ-cultured human HFs
were cultured with SCF (20 ngml1) for 6 days. As expected,
this revealed that SCF significantly increased the number of
Kitþ human CTS (Figure 4a). Next, we investigated whether
CRH exerted any effects on SCF production by microdis-
sected, organ-cultured human HFs. Indeed, 107 M CRH
stimulated follicular SCF expression at the mRNA and protein
levels. SCF-IR was upregulated by CRH in both the outer root
sheath and the CTS (Figure 4b), as confirmed by quantitative
immunohistomorphometry (Figure 4c). Using reverse tran-
scription–PCR, we found that CRH treatment enhanced
the intrafollicular steady-state levels of SCF mRNA in the
proximal HF (Figure 4c, d). Thus, two compartments of
the human HF that are positive for CRH-R1/2 (Figure 3e)
respond to CRH stimulation by upregulating expression of the
Kit ligand, SCF.
To probe the extent to which stimulatory effects of CRH on
resident MC precursors depend on SCF, we cocultured HFs
with CRH and anti-SCF neutralizing antibody. As shown in
Figure 4a, this suppressed the CRH-induced upregulation in
the number of Kitþ cells, suggesting that CRH increases the
number of CTS MCs, at least predominantly, by stimulating
the local HF production of SCF.
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CRH induces MC degranulation via SCF stimulation in
full-thickness skin organ culture
Finally, we wished to establish whether the observed MC-
activating effects of CRH occurred not only in microdis-
sected, amputated, and therefore traumatized anagen VI
scalp HFs, but also in normal, organ-cultured full-thickness
human scalp skin, where the (as yet poorly characterized)
physiological niches in which human skin MCs reside are
most likely to be intact. As shown in Figure 1d–g, the CRH-
induced degranulation of human CTS MCs in situ was indeed
abrogated when CRH was administered in the presence of
neutralizing anti-SCF antibody. This independently confirms
physiologically relevant, MC-activating effects of CRH in
normal human skin and corroborates that these appear to be
mediated, to a large extent, by the stimulation of intracuta-
neous SCF production (Figure 1d–g).
DISCUSSION
This study underscores the importance of neuroendocrine
controls of human skin MC biology under physiologically
relevant conditions, namely, by the neuropeptide hormone
CRH. In addition, this study provides previously unreported
evidence that mature human skin MCs can be generated from
resident precursors in situ, within normal human tissue. To
the best of our knowledge, it has also been unreported that
CRH influences MC maturation in any species and that this
maturation process recruits the classical MC differentiation-
promoting growth factor SCF as at least one underlying
mechanism of action.
Simultaneously, we introduce here the in situ analysis of
CTS MCs in HF organ culture as an instructive—and to our
knowledge previously unreported—experimental tool for
investigating the differentiation, activation, and function of
normal human MCs within their natural habitat. Moreover,
we show that this assay system provides an optimal model for
investigating the as yet insufficiently characterized (neuro-)
endocrine controls of human MC biology in situ. This
relatively simple and physiologically relevant model both
complements and provides an alternative to the widespread
use of MC leukemia lines in human MC research in vitro.
Corticotropin-releasing hormone is best known as a classic
hypothalamic stress hormone, secreted under conditions of
perceived stress. It serves as the most proximal regulator of
the HPA response axis, resulting in the secretion of
glucocorticoids that suppress the immune response and
encode an adaptive response devoted to the stabilization
and restoration of general homeostasis (Slominski et al.,
2007). During such stress responses, MCs play a key role, for
example, in mediating and controlling neurogenic inflamma-
tion, in and beyond the skin (Maurer et al., 1998; Weber
et al., 2003; Theoharides and Cochrane, 2004; Arck et al.,
2005; Maurer and Metz, 2005; Weller et al., 2006; Metz and
Maurer, 2007). For example, sound-induced psychological
stress increases the number of degranulated MCs in murine
skin (Arck et al., 2001), and sound stress-induced neurogenic
skin inflammation and hair growth inhibition in mice are
almost abrogated in MC-deficient mice (Arck et al., 2005).
The observation that CRH can activate human connective
tissue–type MCs in situ fits well with previous observations
that CRH also induces MC degranulation in rodent skin
(Theoharides et al., 1998) and supports the concept that CRH
may also induce neurogenic inflammation in human skin
(Katsarou-Katsari et al., 2001; Theoharides and Cochrane,
2004; Theoharides et al., 2004; Arck et al., 2006; Paus et al.,
2006).
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asterisks indicate significant differences compared to the vehicle control,
**Po0.05, # arbitrary unit by NIH Image). Bar: (b) 20mm. CRH, corticotropin-
releasing hormone; CTS, connective-tissue sheath; HF, hair follicle; MC, mast
cell; NK, negative control; NS, not significant; ORS, outer root sheath; SCF,
stem cell factor; TSA, tyramide signal amplification.
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The effects of CRH on human CTS MC activation and
maturation reported here correspond well with several
previous reports from other groups. For example, CRH
activates rat skin MCs via a CRH-R1-dependent mechanism
leading to vasodilation and increased vascular permeability
(Theoharides et al., 1998). CRH induces vasodilation in
human skin through MC degranulation (Cromptom et al.,
2003). Not only increased peripheral CRH levels, but also
acute stress activates skin MCs (Theoharides et al., 1998), and
acute stress can activate skin MCs via increased CRH
expression in the skin itself (Theoharides et al., 2003). That
restraint stress-induced skin MC activation is inhibited by
antiserum to CRH (Singh et al., 1999) further underscores the
key role of CRH-R-mediated signaling in this.
Because serum CRH levels in humans are either unde-
tectable or, at the most, in the pM range (Hashimoto et al.,
1993), locally produced CRH-R ligands appear to play the
key role in the control of skin MC functions by CRH-R
stimulation and may operate as autocrine or paracrine, rather
than as an endocrine, hormonal regulators. Rapid CRH
metabolism as well as strong binding to local binding
proteins may prevent CRH from reaching biologically
significant circulating concentrations (Karsalis et al. 1991).
Under physiological conditions, several cutaneous cell
populations and skin appendages (HF, sebaceous gland)
generate CRH mRNA and protein (see Ito et al., 2004a, b; Ito
et al., 2005a for overview; Funasaka et al., 1999; Slominski
et al., 1999; Kono et al., 2001; Zouboulis et al., 2002;
Slominski et al., 2007). Also, human HFs respond directly to
CRH stimulation in a manner that is strikingly similar to what
is seen in the classic HPA axis, and have established an
autonomic peripheral HPA-axis equivalent (Ito et al., 2005a).
Thus, local production and release of CRH by human HFs
may well serve as the key source for ligands that stimulate
CRH-Rs on human CTS MC in situ.
The high dose of CRH in this study (107 M) was used
because it had shown maximal effects on the human HF
HPA-axis equivalent (Ito et al., 2005a, b) and in cultured
normal human foreskin keratinocytes (Quevedo et al., 2001).
However, this concentration is substantially above normal
human plasma levels (up to 2.5 pM; Hashimoto et al., 1993),
thus bringing the physiological relevance of our findings into
question. However, the actual tissue level of CRH-R ligands is
thought to be much higher, because in addition to CRH,
CRH-related peptides such as urocortin also stimulate CRH-
Rs and are synthesized in human skin and its appendages
(Funasaka et al., 1999; Slominski et al., 1999; Slominski
et al., 2000; Kono et al., 2001; Zouboulis et al., 2002; Ito
et al., 2004a, b and Ito et al., 2005a). Thus, the actual tissue
levels of CRH-R ligands in the immediate vicinity of resident
skin MCs are likely to be much higher than the recognized
CRH serum levels. Given the recognized similarities of the
local neuroendocrine system of skin and placenta (Slominski
et al., 2000; Yang et al., 2006), it also deserves mentioning
that a small percentage of human umbilical cord blood–-
derived MCs contain more than 100 times higher levels of
CRH and urocortin than what was detected in the same
amount of hypothalamus tissue. This suggests that MCs are
not only a target but also a potential source of CRH and
urocortin and could thus engage in both autocrine and
paracrine signaling (Kempuraj et al., 2004).
The fact that the number of Kitþ cells in the human CTS is
considerably higher than the number of MCs detectable by
conventional histochemistry suggests that the CTS of normal
human scalp HFs harbors a large population of immature MC
precursors, which have not yet developed the characteristic
metachromatic granules of mature MCs. Our finding that this
progenitor cell pool can be stimulated by CRH, in long-term
HF organ culture, to give rise to many more Kitþ MCs than
are normally found in the CTS of human scalp HFs, shows
that the CTS in human skin is indeed a potent extramedullary
tissue source for MC production from resident local precursor
cells—as previously seen in murine vibrissa HFs (Kumamoto
et al., 2003). Given that CRH treatment significantly
increases the number of Kitþ or tryptaseþ CTS MCs in
situ, without evidence of a marked, concomitant stimulation
of proliferation of these cells, the numeric increase in Kitþ
CTS cells probably results from CRH-induced maturation
events in resident immature, Kit MC progenitor cells.
Theoretically, the Kitþ round cells emigrating from the
CTS might be melanoblasts and/or melanocyte stem cells
emanating, for example, from the bulge. However, these cells
are located exclusively within the HF epithelium (Nishimura
et al., 2002, 2005). In our study, cultured HFs were
amputated well below the bulge region so that the likelihood
of any contamination with melanocyte stem cells is very low.
In addition, that the emigrating cells showed the character-
istic histochemistry and tryptase IR of mature MCs proves that
these round cells are indeed MCs.
Skin MCs of different species and diverse tissue types
express CRH-Rs. For example, in murine skin, a small
population of perifollicular and perivascular MCs expresses
CRH-Rs (Donelan et al., 2006). Both CRH-R isoforms are
reportedly expressed by the human leukemic MC line
(HMC-1), and human umbilical cord blood-derived MCs
transcribe CRH-R1 and CRH-R2. CRH-R1 protein is present
and functional in the HMC-1 line, and both CRH-R1 and
CRH-R2 are functional in the human umbilical cord blood–-
derived MCs (Cao et al., 2005). Our findings are in line with
these reports and suggest that, in principle, at least some
human CTS MCs can respond directly to stimulation by CRH.
However, as CRH upregulated intrafollicular SCF expression
on the gene and protein levels and SCF-neutralizing
antibodies abrogated the MC activation by CRH, a major
share of the CRH-induced effects on human CTS MCs seems
to be indirectly mediated by a previously unknown regulatory
loop between CRH-R-mediated neuroendocrine signaling on
the one hand and SCF gene expression and SCF production
on the otherhand.
Two important open questions are from which level of the
CTS, and from which CTS cell population exactly, the CRH-
induced increase in the number of Kitþ /tryptaseþ MCs is
derived. Kumamoto et al. (2003) dissected mouse vibrissa
HFs into three fragments and cultured them in the presence of
SCF. Among them, 70% of the intermediate fragments,
containing the bulge region, showed distinct outgrowth of
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round cells with an MC phenotype, whereas these cells
were observed in only 20% of the upper and lower vibrissa
HF fragments. Here, we used only amputated, lower-scalp
HF fragments, cut at the junction between dermis and
subcutis, which did not contain the bulge area and thus
excluded the special, bulge-associated HF mesenchyme
(Kloepper et al., 2008). Therefore, the generation of
mature MCs from resident precursor cells is likely to be
independent of the bulge-associated HF mesenchyme and
appears to be a general property of the proximal CTS of
human scalp HFs.
In conclusion, we show here that human skin is an
important extramedullary reservoir for MC precursors, whose
maturation underlies a neuroendocrine control (i.e., CRH)
that operates in the context of a newly discovered regulatory
loop between CRH and SCF signaling. To our knowledge this
result has not previously been reported.
MATERIALS AND METHODS
Human HF and full-thickness skin organ culture
Human frontotemporal scalp skin specimens were obtained with
informed consent from eight female patients aged 48–69 years
(mean, 61) undergoing routine face-lift surgery, adhering to the
Declaration of Helsinki Principles and with permission from the
ethics committee of the University of Lu¨beck. Anagen VI HFs were
microdissected as described (Philpott et al., 1994; Ito et al., 2005a)
and treated with vehicle (phosphate-buffered saline) or 107 M CRH
(Sigma-Aldrich, Taufkirchen, Germany) for 2–6 days in Williams’s E
medium.
To culture CTS MC precursor, we cultured microdissected human
HFs in complete RPMI 1640 medium at 37 1C in a CO2 incubator.
Individual fragments were placed on a six-well plate, sandwiched
with a cover glass, and cultured for 4 weeks. Culture medium was
replaced every 3 days and the cover glass was carefully removed
after 4 weeks (Kumamoto et al., 2003).
Human full-thickness skin organ culture was performed as
described previously (Lu et al., 2007). Skin biopsies (three or
four pieces per group) were treated for 48 hours with vehicle
(Williams’s E medium), 107 M CRH, or 107 M CRH and 5 mgml1
anti-SCF antibody (R&D Systems, Wiesbaden-Nordenstadt,
Germany).
Giemsa, toluidine blue, and Leder esterase histochemistry
For detection of MCs and their characteristic metachromatic
granules, three sensitive histochemical staining methods were used
on 8 mm cryosections: Giemsa (Paus et al., 1998), toluidine blue (Ito
et al., 2005b), and Leder esterase. For Leder esterase, slides were
fixed in acetone. Incubating medium consisting of naphthol-ASD-
chloroacetate (10mg; Sigma-Aldrich), N,N-dimethylformamide
(1ml; Sigma-Aldrich), So¨rensen working buffer (35ml, So¨rensen A:
Na2HPO4 (X98%, USP, water free); Roth, Karlsruhe, Germany;
So¨rensen B: KH2PO4; Merck, Darmstadt, Germany), and nitrosylated
pararosaniline (pararosaniline and sodium nitrite; Merck) was
prepared immediately before use. Cryoslides were kept in incubating
medium for 40minutes, counterstained with hematoxylin for
30 seconds, and dehydrated. MCs were classified as ‘‘degranulated’’
when five or more extracellularly located metachromatic granules
could be detected histochemically at magnification.
Immunohistochemistry and quantitative
immunohistomorphometry
For the detection of CRH-R 1/2, Kit, tryptase, and SCF, the highly
sensitive TSA technique (PerkinElmer, Boston, MA) was applied.
Cryosections were incubated with goat antibodies against human
CRH-R1/2 (Santa Cruz Biotechnology, Santa Cruz, CA), Kit (Santa
Cruz Biotechnology), tryptase (Abcam, Cambridge, UK), or SCF
(Santa Cruz Biotechnology) diluted in TNB at 1:1000 (Tris, NaOH,
blocking reagent) for CRH-R1/2, Kit, and SCF and 1:400 for tryptase,
incubated overnight at 4 1C, followed by incubation with the
biotinylated antibody against goat IgG (Immunotech, Glendale,
CA) (1:200 in TNB, 30minutes at room temperature). The TSA
method was applied according to the manufacturer’s protocol. We
purposely used an antibody that recognized both CRH-Rs (Zouboulis
et al., 2002), as it is, as yet, unclear which CRH-R subtype is
expressed by human CTS MCs in situ. Double staining for CRH-R 1/2
and Kit was performed by using the combination of TSA technique
for CRH-R 1/2 staining and indirect immunofluorescent antibody for
Kit. Briefly, after the overnight incubation of sections at 4 1C with
primary antibodies, goat anti-human CRH-R1/2 (1:200; Santa Cruz
Biotechnology) and rabbit anti-human Kit antibody (1:400, diluted in
TNB; Dako, Hamburg, Germany), the sections were incubated with
the biotinylated mouse anti-goat IgG (1:200, diluted in TNB,
45minutes at room temperature; Jackson Immunoresearch Labora-
tories, West Grove, PA). After being washed with TNT wash buffer,
the sections were incubated with goat anti-rabbit Alexa Fluor 594
(1:200 diluted in TNB, 45minutes at room temperature; Invitrogen,
Eugene, OR). The rest of the procedure was according to the TSA
manufacturer’s protocol.
Proliferation was detected by Ki-67 staining as described (Bodo´
et al., 2007). Microdissected human HFs were cultured in complete
RPMI 1640 medium for 4 weeks, and the cells emerging from the
CTS were directly immunostained for Kit, using the avidin–biotin
complex technique following the manufacturer’s directions (Histos-
tain Plus Kit; Zymed Laboratories, South San Francisco, CA).
The mean fluorescence intensity of carefully selected, standar-
dized reference areas was measured using NIH Image software
(National Institutes of Health, Bethesda, MD). This method has
proven to be a very sensitive and highly reproducible technique for
the semiquantitative assessment of significant IR changes in situ (Ito
et al., 2004b).
RT-PCR
To detect SCF or c-Kit mRNA, the total RNA was extracted from HFs
after 1-day culture, using the RNeasy kit (Qiagen, Hilden, Germany),
and first-strand cDNA was synthesized using the First Strand cDNA
Synthesis Kit (Roche, Mannheim, Germany). The primers used in this
study were as follows—c-Kit sense: 50-GAGTTGGCCCTAGAAGTT
AGA-30, anti-sense: 50-CCTGGAGGTGGATGCAAGTT-30 (GenBank
accession number X06182); SCF sense: 50-ATTCAAGAGCCCAGA
ACCCA-30, anti-sense: 50-CTGTTAACCAGCCAATGTAC-30 (Gen-
Bank accession number NM003994); b-actin sense: 50-CGACAAC
GGCTCCGGCATGTGC-30, anti-sense: 50-CGTCACCGGAGTCCAT
CACGATGC-30 (GenBank accession number NM001101). PCR
amplification for SCF was performed on the UNO-Thermoblock
(Biometra, Go¨ttingen, Germany) as follows: a denaturing step at
94 1C for 5minutes, 35 cycles of 94 1C for 30 seconds, 55 1C for
1minute, and 72 1C for 2minutes, and final extension at 72 1C for
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7minutes. The PCR products were run on a 2% agarose gel
containing 0.02mgml1 ethidium bromide and visualized by the UV
transilluminator. The intensity of mRNA expression was measured by
the relative density against b-actin using ImageJ software (NIH).
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